NASDAQ:SLRN Acelyrin (SLRN) Stock Price, News & Analysis → Biden replacement revealed? (From Paradigm Press) (Ad) Free SLRN Stock Alerts $4.10 -0.02 (-0.49%) (As of 06/3/2024 ET) Add Compare Share Share Today's Range$4.05▼$4.4250-Day Range$4.05▼$6.7552-Week Range$3.91▼$29.88Volume906,012 shsAverage Volume1.14 million shsMarket Capitalization$406.02 millionP/E RatioN/ADividend YieldN/APrice Target$12.80 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Acelyrin alerts: Email Address Acelyrin MarketRank™ Stock AnalysisAnalyst RatingHold2.40 Rating ScoreUpside/Downside212.2% Upside$12.80 Price TargetShort InterestHealthy11.18% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment1.27Based on 4 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($3.33) to ($4.08) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.52 out of 5 starsMedical Sector502nd out of 927 stocksPharmaceutical Preparations Industry235th out of 439 stocks 3.2 Analyst's Opinion Consensus RatingAcelyrin has received a consensus rating of Hold. The company's average rating score is 2.40, and is based on 2 buy ratings, 3 hold ratings, and no sell ratings.Amount of Analyst CoverageAcelyrin has only been the subject of 2 research reports in the past 90 days.Read more about Acelyrin's stock forecast and price target. Previous Next 3.0 Short Interest Percentage of Shares Shorted11.18% of the float of Acelyrin has been sold short.Short Interest Ratio / Days to CoverAcelyrin has a short interest ratio ("days to cover") of 6.1.Change versus previous monthShort interest in Acelyrin has recently decreased by 17.70%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldAcelyrin does not currently pay a dividend.Dividend GrowthAcelyrin does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for SLRN. Previous Next 3.5 News and Social Media Coverage News SentimentAcelyrin has a news sentiment score of 1.27. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.77 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Acelyrin this week, compared to 3 articles on an average week.Search Interest2 people have searched for SLRN on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Acelyrin to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Acelyrin insiders have not sold or bought any company stock.Percentage Held by Insiders13.60% of the stock of Acelyrin is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions87.31% of the stock of Acelyrin is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Acelyrin's insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Acelyrin are expected to decrease in the coming year, from ($3.33) to ($4.08) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Acelyrin is -1.72, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Acelyrin is -1.72, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAcelyrin has a P/B Ratio of 0.61. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Acelyrin's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Weiss RatingsProtect Your Bank Account Before It’s Too LateFor months I’ve been warning about the federal government’s terrifying new program to control every American’s bank account. It gives them the power to monitor every single transaction …Stop right now and do these 3 things to protect yourself About Acelyrin Stock (NASDAQ:SLRN)Acelyrin, Inc., a clinical biopharma company, focuses on identifying, acquiring, and accelerating the development and commercialization of transformative medicines. The company's lead product candidate is izokibep, a small protein therapeutic designed to inhibit IL-17A with high potency, which is in Phase 3 clinical trials for use in the treatment of Hidradenitis Suppurativa, Psoriatic Arthritis, and uveitis, as well as in Phase 2 clinical trials for use in the treatment of Axial Spondyloarthritis. It is also developing lonigutamab, a humanized immunoglobulin G1 (IgG1) monoclonal antibody which is in Phase 1 clinical trials for use in the treatment of thyroid eye disease. In addition, the company's develops SLRN-517, a fully human IgG1 monoclonal antibody targeting c-KIT, which is in preclinical stage for use in the treatment of chronic urticaria. Acelyrin, Inc. was incorporated in 2020 and is headquartered in Agoura Hills, California.Read More SLRN Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart SLRN Stock News HeadlinesMay 29, 2024 | globenewswire.comACELYRIN, INC. Announces Lonigutamab Phase 1/2 Proof-Of-Concept Data to be Shared During Late-Breaking Oral Presentation at ENDO 2024May 25, 2024 | americanbankingnews.comQ2 2024 Earnings Estimate for Acelyrin, Inc. (NASDAQ:SLRN) Issued By HC WainwrightMay 18, 2024 | finance.yahoo.comAcelyrin, Inc. (SLRN)May 15, 2024 | markets.businessinsider.comBuy Rating Affirmed for ACELYRIN, INC. on Solid Financials and Promising PipelineMay 15, 2024 | investorplace.comSLRN Stock Earnings: Acelyrin Beats EPS for Q1 2024May 15, 2024 | markets.businessinsider.comACELYRIN, INC.: Strong Buy Recommendation on Promising Izo Drug Prospects and Strategic AdvancementsMay 9, 2024 | marketwatch.comAcelyrin Founder Steps Down as CEOMay 9, 2024 | msn.comAcelyrin names Mina Kim as new Chief Executive OfficerMay 9, 2024 | finance.yahoo.comACELYRIN, INC. Announces Leadership TransitionMay 9, 2024 | globenewswire.comACELYRIN, INC. Provides Business Update and Highlights Key Upcoming MilestonesApril 29, 2024 | globenewswire.comACELYRIN, INC. to Report First Quarter 2024 Financial Results and Corporate Update on May 13, 2024April 1, 2024 | msn.comStocks Pressured as Bond Yields Jump on Strength in US ManufacturingApril 1, 2024 | markets.businessinsider.comACELYRIN, INC.: Promising Clinical Trials and Market Opportunity Justify Buy RatingMarch 28, 2024 | investorplace.comSLRN Stock Earnings: Acelyrin Beats EPS for Q4 2023March 28, 2024 | finance.yahoo.comACELYRIN, INC. Reports Full Year 2023 Financial Results and Recent HighlightsMarch 28, 2024 | globenewswire.comACELYRIN, INC. Reports Full Year 2023 Financial Results and Recent HighlightsMarch 20, 2024 | markets.businessinsider.comBuy Rating on ACELYRIN, INC.: Promising Clinical Prospects for Novel TED Therapy LonigutamabMarch 20, 2024 | markets.businessinsider.comAcelyrin Announces Positive Phase 1/2 Data For Lonigutamab In Thyroid Eye Disease; Stock UpMarch 20, 2024 | msn.comInvestors Cheer Acelyrin's Stock, Its Second Lead Candidate Shows Clinical Benefit In Thyroid Eye Disease PatientsMarch 20, 2024 | finance.yahoo.comACELYRIN, INC. Announces Positive Phase 1/2 Proof-of-Concept Data for Lonigutamab, First Subcutaneous Anti-IGF-1R to Demonstrate Clinical Responses in Thyroid Eye DiseaseMarch 18, 2024 | finance.yahoo.comSLRN Apr 2024 2.500 putMarch 12, 2024 | seekingalpha.comAcelyrin: Analyzing Its Recovery And Potential In Psoriatic ArthritisMarch 12, 2024 | markets.businessinsider.comHold Rating Affirmed for ACELYRIN, INC. as Izokibep Faces Competitive Hurdles and Safety ConcernsMarch 11, 2024 | marketwatch.comAcelyrin Stock Climbs 10% on Positive Results for Arthritis TreatmentMarch 11, 2024 | msn.comAcelyrin's Lead Drug Candidate Hits Primary Goal In Late-Stage Psoriatic Arthritis StudySee More Headlines Receive SLRN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Acelyrin and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/28/2024Today6/03/2024Next Earnings (Estimated)8/12/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:SLRN CUSIPN/A CIK1962918 Webwww.acelyrin.com Phone805-730-0360FaxN/AEmployees135Year FoundedN/APrice Target and Rating Average Stock Price Target$12.80 High Stock Price Target$18.00 Low Stock Price Target$8.00 Potential Upside/Downside+212.2%Consensus RatingHold Rating Score (0-4)2.40 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($2.38) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-381,640,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-35.33% Return on Assets-32.55% Debt Debt-to-Equity RatioN/A Current Ratio13.27 Quick Ratio13.27 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$6.74 per share Price / Book0.61Miscellaneous Outstanding Shares99,030,000Free Float85,559,000Market Cap$406.02 million OptionableOptionable BetaN/A Investing Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free Report Key ExecutivesMs. Melanie Gloria B.S.N. (Age 46)Chief Operating Officer Comp: $667.52kMs. Mina Kim (Age 50)CEO & Director Mr. Gilbert M. Labrucherie J.D. (Age 52)CFO & Chief Business Officer Mr. Tyler MarciniakHead of Investor Relations & CommunicationsMs. Sanam Pangali J.D.Chief Legal Officer & Head of PeopleDr. Paul M. Peloso M.D. (Age 66)M.Sc., Chief Medical Officer Ms. Suzy Buckhalter CPASenior Director of Finance & AccountingMr. Kenneth A. Lock (Age 50)Chief Commercial Officer Dr. Shephard Mpofu M.D.Chief Medical OfficerMs. Patricia A. Turney (Age 57)Chief Technical Operations Officer More ExecutivesKey CompetitorsEvotecNASDAQ:EVOSchrödingerNASDAQ:SDGRArdelyxNASDAQ:ARDXKura OncologyNASDAQ:KURAStructure TherapeuticsNASDAQ:GPCRView All CompetitorsInsiders & InstitutionsOpaleye Management Inc.Sold 2,566,138 shares on 5/29/2024Ownership: 1.596%Virtu Financial LLCBought 21,834 shares on 5/20/2024Ownership: 0.022%Artal Group S.A.Sold 630,745 shares on 5/17/2024Ownership: 2.429%Ikarian Capital LLCSold 763,565 shares on 5/17/2024Ownership: 1.580%Kennedy Capital Management LLCBought 12,554 shares on 5/16/2024Ownership: 0.492%View All Insider TransactionsView All Institutional Transactions SLRN Stock Analysis - Frequently Asked Questions Should I buy or sell Acelyrin stock right now? 5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Acelyrin in the last year. There are currently 3 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" SLRN shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in SLRN, but not buy additional shares or sell existing shares. View SLRN analyst ratings or view top-rated stocks. What is Acelyrin's stock price target for 2024? 5 brokers have issued 12-month price targets for Acelyrin's shares. Their SLRN share price targets range from $8.00 to $18.00. On average, they expect the company's share price to reach $12.80 in the next twelve months. This suggests a possible upside of 212.2% from the stock's current price. View analysts price targets for SLRN or view top-rated stocks among Wall Street analysts. How have SLRN shares performed in 2024? Acelyrin's stock was trading at $7.46 at the beginning of 2024. Since then, SLRN shares have decreased by 45.0% and is now trading at $4.10. View the best growth stocks for 2024 here. Are investors shorting Acelyrin? Acelyrin saw a drop in short interest in the month of May. As of May 15th, there was short interest totaling 7,020,000 shares, a drop of 17.7% from the April 30th total of 8,530,000 shares. Based on an average trading volume of 1,160,000 shares, the short-interest ratio is presently 6.1 days. Currently, 11.2% of the shares of the company are sold short. View Acelyrin's Short Interest. When is Acelyrin's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, August 12th 2024. View our SLRN earnings forecast. How were Acelyrin's earnings last quarter? Acelyrin, Inc. (NASDAQ:SLRN) posted its quarterly earnings results on Thursday, March, 28th. The company reported ($0.75) EPS for the quarter, beating the consensus estimate of ($1.00) by $0.25. When did Acelyrin IPO? Acelyrin (SLRN) raised $540 million in an initial public offering on Friday, May 5th 2023. The company issued 30,000,000 shares at $18.00 per share. Who are Acelyrin's major shareholders? Acelyrin's stock is owned by many different retail and institutional investors. Top institutional investors include Vanguard Group Inc. (6.31%), Artal Group S.A. (2.43%), Opaleye Management Inc. (1.60%), Ikarian Capital LLC (1.58%), StemPoint Capital LP (0.72%) and Jacobs Levy Equity Management Inc. (0.59%). Insiders that own company stock include Beth C Seidenberg, Biopartners Fund Ii Westlake, Mardi Dier, Ronald Oyston and Shao-Lee Lin. View institutional ownership trends. How do I buy shares of Acelyrin? Shares of SLRN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:SLRN) was last updated on 6/3/2024 by MarketBeat.com Staff From Our PartnersShocking $16T Elon Musk Crypto LeakCrypto 101 MediaThe Only Energy Play You Should Be Looking AtWealthpin Pro[Webinar] Understanding Covered CallsOICWas the Great Financial Crisis fun?Brooks EnterprisesWhat’s Pelosi Buying Now?AltimetryAlex's "Next Magnificent Seven" StocksThe Oxford ClubWrite this ticker symbol down…StocksToTradeClaim Your Complimentary Bitcoin RewardCrypto Swap Profits Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Acelyrin, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
